CN107602564A - 布鲁顿酪氨酸激酶抑制剂 - Google Patents
布鲁顿酪氨酸激酶抑制剂 Download PDFInfo
- Publication number
- CN107602564A CN107602564A CN201710849859.3A CN201710849859A CN107602564A CN 107602564 A CN107602564 A CN 107602564A CN 201710849859 A CN201710849859 A CN 201710849859A CN 107602564 A CN107602564 A CN 107602564A
- Authority
- CN
- China
- Prior art keywords
- substituted
- compound
- rings
- bases
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 Cc1c(C(CC2)=CCC2NC(C#CC)=*)[n](ccnc2N)c2c1-c(cc1)ccc1C(Nc1nccc(C)c1)=[U] Chemical compound Cc1c(C(CC2)=CCC2NC(C#CC)=*)[n](ccnc2N)c2c1-c(cc1)ccc1C(Nc1nccc(C)c1)=[U] 0.000 description 6
- OWCWAUHZXXLCGQ-QESANXMHSA-N CC#CC(NC(CC1)CC=C1c1nc(-c2ccc(C(Nc3cc(C#N)ccn3)O)cc2)c2[n]1[C@@H](C1)C1N=C2N)=O Chemical compound CC#CC(NC(CC1)CC=C1c1nc(-c2ccc(C(Nc3cc(C#N)ccn3)O)cc2)c2[n]1[C@@H](C1)C1N=C2N)=O OWCWAUHZXXLCGQ-QESANXMHSA-N 0.000 description 1
- ZPFIIXLKQCJMSM-VXPUYCOJSA-N CC(C)C(C)c1c(-c(cc2)ccc2C(NC2C=CC=CCC2)=O)nc(C(CC2)=CCC2NC(C)=O)[n]1/C=C\N Chemical compound CC(C)C(C)c1c(-c(cc2)ccc2C(NC2C=CC=CCC2)=O)nc(C(CC2)=CCC2NC(C)=O)[n]1/C=C\N ZPFIIXLKQCJMSM-VXPUYCOJSA-N 0.000 description 1
- DLLOMAQYMBDBSH-UHFFFAOYSA-N CC(C1)C(C(N)=O)=CC=C1c1c(c(NCc(ccc(OC)c2)c2OC)ncc2)[n]2c(C(CC2)=CCC2NC(OC(C)(C)C)=O)n1 Chemical compound CC(C1)C(C(N)=O)=CC=C1c1c(c(NCc(ccc(OC)c2)c2OC)ncc2)[n]2c(C(CC2)=CCC2NC(OC(C)(C)C)=O)n1 DLLOMAQYMBDBSH-UHFFFAOYSA-N 0.000 description 1
- QJNWXUZDRLLKFE-UHFFFAOYSA-N CCCC(C1)C=CN=C1NC(c1ccc(-c2c(c(N)ncc3)[n]3c(C(CC3)=C=CC3NC(C#CC)=O)n2)c(OC)c1)=O Chemical compound CCCC(C1)C=CN=C1NC(c1ccc(-c2c(c(N)ncc3)[n]3c(C(CC3)=C=CC3NC(C#CC)=O)n2)c(OC)c1)=O QJNWXUZDRLLKFE-UHFFFAOYSA-N 0.000 description 1
- RYAALHCJZMCRAJ-UHFFFAOYSA-N COC(c(cc1)ccc1-c1c(c(NCc(ccc(OC)c2)c2OC)ncc2)[n]2c(Br)n1)=O Chemical compound COC(c(cc1)ccc1-c1c(c(NCc(ccc(OC)c2)c2OC)ncc2)[n]2c(Br)n1)=O RYAALHCJZMCRAJ-UHFFFAOYSA-N 0.000 description 1
- LPMMDMUDSRORAW-UHFFFAOYSA-N COC(c1ccc(C(c2nccnc2Cl)N)cc1)=O Chemical compound COC(c1ccc(C(c2nccnc2Cl)N)cc1)=O LPMMDMUDSRORAW-UHFFFAOYSA-N 0.000 description 1
- IDZQEQPZARAUMH-UHFFFAOYSA-N N#Cc1ccnc(NC(c2ccc(B(O)O)cc2)=O)c1 Chemical compound N#Cc1ccnc(NC(c2ccc(B(O)O)cc2)=O)c1 IDZQEQPZARAUMH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Description
Claims (23)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710849859.3A CN107602564B (zh) | 2017-09-20 | 2017-09-20 | 布鲁顿酪氨酸激酶抑制剂 |
PCT/CN2017/107638 WO2019056466A1 (zh) | 2017-09-20 | 2017-10-25 | 布鲁顿酪氨酸激酶抑制剂 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710849859.3A CN107602564B (zh) | 2017-09-20 | 2017-09-20 | 布鲁顿酪氨酸激酶抑制剂 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107602564A true CN107602564A (zh) | 2018-01-19 |
CN107602564B CN107602564B (zh) | 2019-08-30 |
Family
ID=61061204
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710849859.3A Active CN107602564B (zh) | 2017-09-20 | 2017-09-20 | 布鲁顿酪氨酸激酶抑制剂 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN107602564B (zh) |
WO (1) | WO2019056466A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020063012A1 (zh) * | 2018-09-29 | 2020-04-02 | 南京亘泰医药技术有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
CN111377928A (zh) * | 2018-12-28 | 2020-07-07 | 南京艾德凯腾生物医药有限责任公司 | 一种制备Acalabrutinib的方法 |
RU2809188C2 (ru) * | 2018-09-29 | 2023-12-07 | Транстера Сайенсиз (Наньцзин), Инк. | Аминонорборнановое производное и способ его получения, а также его применение |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101674834A (zh) * | 2007-03-28 | 2010-03-17 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton’s tyrosine kinase)抑制剂 |
WO2014113942A1 (en) * | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016109223A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
CN103889987B (zh) * | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
WO2016196418A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
CN106831789A (zh) * | 2016-12-21 | 2017-06-13 | 南京亘泰医药技术有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
-
2017
- 2017-09-20 CN CN201710849859.3A patent/CN107602564B/zh active Active
- 2017-10-25 WO PCT/CN2017/107638 patent/WO2019056466A1/zh active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101674834A (zh) * | 2007-03-28 | 2010-03-17 | 环状药物公司 | 布鲁顿氏酪氨酸激酶(Bruton’s tyrosine kinase)抑制剂 |
CN103889987B (zh) * | 2011-07-19 | 2016-09-14 | 默沙东有限责任公司 | 作为btk抑制剂的选择的咪唑并吡嗪类 |
WO2014113942A1 (en) * | 2013-01-23 | 2014-07-31 | Merck Sharp & Dohme Corp. | Btk inhibitors |
WO2016109223A1 (en) * | 2014-12-31 | 2016-07-07 | Merck Sharp & Dohme Corp. | Benzamide imidazopyrazine btk inhibitors |
WO2016196418A1 (en) * | 2015-06-04 | 2016-12-08 | Merck Sharp & Dohme Corp. | Btk inhibitors |
CN106831789A (zh) * | 2016-12-21 | 2017-06-13 | 南京亘泰医药技术有限公司 | 布鲁顿酪氨酸激酶抑制剂 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020063012A1 (zh) * | 2018-09-29 | 2020-04-02 | 南京亘泰医药技术有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
CN110964016A (zh) * | 2018-09-29 | 2020-04-07 | 南京亘泰医药技术有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
CN112135826A (zh) * | 2018-09-29 | 2020-12-25 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
CN110964016B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
CN112135826B (zh) * | 2018-09-29 | 2021-05-28 | 南京药捷安康生物科技有限公司 | 氨基降茨烷衍生物及其制备方法与应用 |
JP2022501403A (ja) * | 2018-09-29 | 2022-01-06 | 南京薬捷安康生物科技有限公司Nanjing Transthera Biosciences Co., Ltd. | アミノノルカンファン誘導体及びその製造方法と使用 |
US11420975B2 (en) | 2018-09-29 | 2022-08-23 | Transthera Sciences (Nanjing), Inc. | Substituted imidazo[1,5-a]pyrazines as Bruton's tyrosine kinase inhibitors |
JP7370617B2 (ja) | 2018-09-29 | 2023-10-30 | 薬捷安康(南京)科技股▲分▼有限公司 | アミノノルカンファン誘導体及びその製造方法と使用 |
RU2809188C2 (ru) * | 2018-09-29 | 2023-12-07 | Транстера Сайенсиз (Наньцзин), Инк. | Аминонорборнановое производное и способ его получения, а также его применение |
CN111377928A (zh) * | 2018-12-28 | 2020-07-07 | 南京艾德凯腾生物医药有限责任公司 | 一种制备Acalabrutinib的方法 |
Also Published As
Publication number | Publication date |
---|---|
CN107602564B (zh) | 2019-08-30 |
WO2019056466A1 (zh) | 2019-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111377917B (zh) | 杂环类化合物、中间体、其制备方法及应用 | |
AU2017294231B2 (en) | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | |
JP6409116B2 (ja) | プロテインキナーゼ阻害剤としてのアミノピリダジノン化合物 | |
CN106831789A (zh) | 布鲁顿酪氨酸激酶抑制剂 | |
CN108602776B (zh) | 用作irak抑制剂的杂芳基化合物及其用途 | |
CN106573937B (zh) | 作为fshr调节剂的吡唑化合物及其用途 | |
CN102229605B (zh) | 关于hiv整合酶的n-取代的羟基嘧啶酮甲酰胺抑制剂 | |
JP2022505987A (ja) | Tyk2阻害剤およびその使用 | |
KR102215172B1 (ko) | 이미다조피라진아민 페닐 유도체 및 그의 용도 | |
CN105837576B (zh) | Btk抑制剂 | |
CN106496209B (zh) | 用作atr激酶抑制剂的化合物 | |
CN101583598B (zh) | 具有IκB激酶β抑制活性的新型吲哚衍生物 | |
CN105315285B (zh) | 2,4‑二取代7H‑吡咯并[2,3‑d]嘧啶衍生物、其制法与医药上的用途 | |
TW201704237A (zh) | 適用於治療與kit及pdfgr相關之病症的組合物 | |
TW202115065A (zh) | Kras突變蛋白抑制劑 | |
CN108137603A (zh) | 氮杂环丁烷衍生物、其制备方法及用途 | |
CN105934432A (zh) | 2,4-二取代苯-1,5-二胺衍生物及其应用以及由其制备的药物组合物和药用组合物 | |
EP1505061A1 (en) | Compound exhibiting pgd 2 receptor antagonism | |
KR20080095902A (ko) | 단백질 키나제의 억제제로서 유용한 디하이드로디아제핀 | |
JP2022524974A (ja) | Tyk2阻害剤およびその使用 | |
EP3124486B1 (en) | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof | |
CN111433196A (zh) | 新颖缓激肽b2受体拮抗剂及其用途 | |
JP2022525069A (ja) | Rad51インヒビター | |
JP6918827B2 (ja) | 新規なn−[(ピリジルオキシ)プロパニル]ベンズアミド | |
JP5620393B2 (ja) | 脳梗塞治療薬 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information | ||
CB02 | Change of applicant information |
Address after: Room 1008, Building D6, No. 9 Weidi Road, Xianlin University Town, Xianlin Street, Qixia District, Nanjing, Jiangsu Province, 210000 Applicant after: Nanjing gentai Medical Technology Co Ltd Address before: Room 401, No. 27, Jinwan Garden, Nanjing, Jiangsu Province Applicant before: Nanjing gentai Medical Technology Co Ltd |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20201021 Address after: 4 / F, building 02, phase II of biomedical Valley accelerator, Jiangbei new district, Nanjing, Jiangsu Province, 210000 Patentee after: Nanjing TransThera Biosciences Co.,Ltd. Address before: Room 1008, Building D6, No. 9 Weidi Road, Xianlin University Town, Xianlin Street, Qixia District, Nanjing, Jiangsu Province, 210000 Patentee before: NANJING GENTAI PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 210000 4th floor, building 02, biomedical Valley accelerator phase II, Jiangbei new district, Nanjing City, Jiangsu Province Patentee after: Yaojie Ankang (Nanjing) Technology Co.,Ltd. Address before: 210000 4th floor, building 02, biomedical Valley accelerator phase II, Jiangbei new district, Nanjing City, Jiangsu Province Patentee before: NANJING TRANSTHERA BIOSCIENCES Co.,Ltd. |